z-logo
open-access-imgOpen Access
Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies
Author(s) -
Suanna S. Bruinooge,
Shimere Sherwood,
Stephen Grubbs,
Richard L. Schilsky
Publication year - 2019
Publication title -
journal of oncology practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.555
H-Index - 60
eISSN - 1935-469X
pISSN - 1554-7477
DOI - 10.1200/jop.19.00262
Subject(s) - medicine , targeted therapy , somatic cell , precision medicine , companion diagnostic , precision oncology , mutation , bioinformatics , drug , drug resistance , biomarker , cancer , oncology , computational biology , cancer research , pharmacology , pathology , gene , genetics , biology
Targeted cancer therapies are drugs and biologics designed to affect cancer cell growth by blocking or interfering with specific molecular pathways in the cancer cell. Use of targeted agents usually requires verification through molecular testing that the patient's tumor harbors the molecular biomarker that is the target of the drug or is predictive of treatment benefit. Genomic mutations may be clinically actionable if they are associated with response or resistance to a potential therapy. If a genomic test reveals an actionable alteration, there are several options for accessing the targeted therapy. This article is intended to help clinicians determine if a tumor mutation is potentially treatable with a marketed or investigational drug or biologic product and to offer guidance on how to access the product of interest.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom